Виды и рода войск ВС
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
Виды и рода войск ВС РФ
Узнайте о Виды и рода войск ВС РФ в энциклопедии магазина Форма одежды.
*Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales*
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. “With a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizer’s long-term growth potential,” said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/pfizer-posts-narrower-q3-loss-amid-slumping-covid-vaccine-sales)
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. “With a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizer’s long-term growth potential,” said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/pfizer-posts-narrower-q3-loss-amid-slumping-covid-vaccine-sales)
TheStreet
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. “With a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizer’s long-term growth potential,” said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. “With a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizer’s long-term growth potential,” said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
TheStreet
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
*RosHunter =?UTF-8?B?0JrRg9C/0LjRgtGMIC0g0KTQvtGA0LzQsCDQvtC00LXQttC00Ys=?=*
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3576492.html)
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3576492.html)
Forma-Odezhda
Купить Товары RosHunter Купить
Купить Товары Одежда для охотников под торговой маркой «RosHunter» отличается высоким качеством изготовления и долговечностью в эксплуатации. Её давно оценили люди, чьей страстью является охота . Наш девиз: «Качество и стиль», хорошо знаком всем нашим по
RosHunter =?UTF-8?B?0JrRg9C/0LjRgtGMIC0g0KTQvtGA0LzQsCDQvtC00LXQttC00Ys=?=
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
Купить Товары RosHunter Купить
Купить Товары Одежда для охотников под торговой маркой «RosHunter» отличается высоким качеством изготовления и долговечностью в эксплуатации. Её давно оценили люди, чьей страстью является охота . Наш девиз: «Качество и стиль», хорошо знаком всем нашим по
*ГОСТ Р*
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3577485.html)
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3577485.html)
Forma-Odezhda
ГОСТ Р 12.4.189-99 СИЗОД Маски
Узнайте о ГОСТ Р 12.4.189-99 СИЗОД Маски в энциклопедии магазина Форма одежды.
ГОСТ Р
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ГОСТ Р 12.4.189-99 СИЗОД Маски
Узнайте о ГОСТ Р 12.4.189-99 СИЗОД Маски в энциклопедии магазина Форма одежды.
*Курсантские погоны*
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572107.html)
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572107.html)
Forma-Odezhda
Курсантские погоны
Узнайте о Курсантские погоны в энциклопедии магазина Форма одежды.
Курсантские погоны
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
Курсантские погоны
Узнайте о Курсантские погоны в энциклопедии магазина Форма одежды.
*We just got our wedding photos and they're awful! Here's the best of the worst*
submitted by /u/CptJaxxParrow to r/pics [link] [comments]
[Read more...](https://www.reddit.com/r/pics/comments/17k98kq/we_just_got_our_wedding_photos_and_theyre_awful/)
submitted by /u/CptJaxxParrow to r/pics [link] [comments]
[Read more...](https://www.reddit.com/r/pics/comments/17k98kq/we_just_got_our_wedding_photos_and_theyre_awful/)
Reddit
We just got our wedding photos and they're awful! Here's the best of the worst : r/pics
34K votes, 4.3K comments. 31M subscribers in the pics community. A place for photographs, pictures, and other images.
We just got our wedding photos and they're awful! Here's the best of the worst
submitted by /u/CptJaxxParrow to r/pics link comments
Read more...
submitted by /u/CptJaxxParrow to r/pics link comments
Read more...
Reddit
We just got our wedding photos and they're awful! Here's the best of the worst : r/pics
34K votes, 4.3K comments. 31M subscribers in the pics community. A place for photographs, pictures, and other images.
*5 самых необычных случаев мошенничества в истории*
Продажа участков страны, которой никогда не было, платная защита от ведьм и похищение Эйфелевой башни.
[Read more...](https://lifehacker.ru/neobychnye-sluchai-moshennichestva/)
Продажа участков страны, которой никогда не было, платная защита от ведьм и похищение Эйфелевой башни.
[Read more...](https://lifehacker.ru/neobychnye-sluchai-moshennichestva/)
*Determinate inflorescence*
Determinate De*ter mi*nate, a. [L. determinatus, p. p. of determinare. See {Determine}.] 1. Having defined limits; not uncertain or arbitrary; fixed; established; definite. [1913 Webster] Quantity of words...
[Read more...](https://enacademic.com/dic.nsf/cide/48461/Determinate)
Determinate De*ter mi*nate, a. [L. determinatus, p. p. of determinare. See {Determine}.] 1. Having defined limits; not uncertain or arbitrary; fixed; established; definite. [1913 Webster] Quantity of words...
[Read more...](https://enacademic.com/dic.nsf/cide/48461/Determinate)
Determinate inflorescence
Determinate Deter minate, a. L. determinatus, p. p. of determinare. See {Determine}. 1. Having defined limits; not uncertain or arbitrary; fixed; established; definite. 1913 Webster Quantity of words...
Read more...
Determinate Deter minate, a. L. determinatus, p. p. of determinare. See {Determine}. 1. Having defined limits; not uncertain or arbitrary; fixed; established; definite. 1913 Webster Quantity of words...
Read more...
*Israeli Offensive in the Gaza Strip as of October 30th 2023*
submitted by /u/Winter-Leadership986 to r/MapPorn [link] [comments]
[Read more...](https://www.reddit.com/r/MapPorn/comments/17k4fmr/israeli_offensive_in_the_gaza_strip_as_of_october/)
submitted by /u/Winter-Leadership986 to r/MapPorn [link] [comments]
[Read more...](https://www.reddit.com/r/MapPorn/comments/17k4fmr/israeli_offensive_in_the_gaza_strip_as_of_october/)
Reddit
From the MapPorn community on Reddit: Israeli Offensive in the Gaza Strip as of October 30th 2023
Explore this post and more from the MapPorn community
Israeli Offensive in the Gaza Strip as of October 30th 2023
submitted by /u/Winter-Leadership986 to r/MapPorn link comments
Read more...
submitted by /u/Winter-Leadership986 to r/MapPorn link comments
Read more...
Reddit
From the MapPorn community on Reddit: Israeli Offensive in the Gaza Strip as of October 30th 2023
Explore this post and more from the MapPorn community
*Holup little man finished third??*
submitted by /u/TheGrimReefah to r/HolUp [link] [comments]
[Read more...](https://www.reddit.com/r/HolUp/comments/17kes7u/holup_little_man_finished_third/)
submitted by /u/TheGrimReefah to r/HolUp [link] [comments]
[Read more...](https://www.reddit.com/r/HolUp/comments/17kes7u/holup_little_man_finished_third/)
Reddit
From the HolUp community on Reddit: Holup little man finished third??
Explore this post and more from the HolUp community
*It's better*
submitted by /u/My_Memes_Will_Cure_U to r/tumblr [link] [comments]
[Read more...](https://www.reddit.com/r/tumblr/comments/17kflu1/its_better/)
submitted by /u/My_Memes_Will_Cure_U to r/tumblr [link] [comments]
[Read more...](https://www.reddit.com/r/tumblr/comments/17kflu1/its_better/)
Reddit
From the tumblr community on Reddit: It's better
Explore this post and more from the tumblr community